Skip to main content

Von Willebrand Disease

Study of Voncento® in Subjects With Von Willebrand Disease
NCT02552576 | PHASE 4 | INTERVENTIONAL

This is a multi-centre, open-label, single-arm, phase 4, post-marketing study to further investigate the efficacy and safety of Voncento in subjects with Von Willebrand Disease (VWD) in whom treatment with a Von Willebrand Factor (VWF) product is required as on-demand therapy, for prophylactic therapy, or during surgery. Subjects will be treated with Voncento either as an on-demand regimen (eg, to treat a non-surgical spontaneous or traumatic bleeding event) or prevention regimen (eg, to prevent an anticipated bleeding event) at a dose prescribed by the Investigator in accordance with the Voncento Summary of Product Characteristics (SmPC), or with a prophylaxis regimen (regular treatment with Voncento at a frequency of 1-3 times per week). Voncento will also be given to prevent and treat any surgical bleeding events.

Trial Information
12 Sites
26 Participants
Recruiting
6 Years to 2 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Site
Vienna,Austria
Study Site
Duisburg,Germany
Study Site
Frankfurt,Germany
Study Site
Athens,Greece
Study Site
Krakow,Poland
Study Site
Rzeszów,Poland
Study Site
Wroclaw,Poland
Study Site
London,United Kingdom
Study Site
London,United Kingdom
Study Site
London,United Kingdom
Study Site
London,United Kingdom
Study Site
London,United Kingdom

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov